Dengue is a globally important mosquito-borne viral infection, with about 4 billion people at risk and 100 million symptomatic cases annually. In 1997, the World Health Organization (WHO) classified symptomatic dengue as dengue fever and dengue hemorrhagic fever, with the latter having 4 grades of severity, where grades III and IV were considered to represent dengue shock syndrome. Dengue hemorrhagic fever is a more severe form of dengue fever, with evident plasma leakage leading to spontaneous bleeding, organ failure or hypovolemic shock. In 2009, the WHO published a new classification for dengue, adding central nervous system (CNS) involvement as a criterion for severe dengue. Complications of CNS involvement in severe dengue include dengue encephalopathy or encephalitis, post-dengue immune-mediated syndromes and cerebrovascular complications. The mediators released during dengue infection, such as cytokines, chemokines and complement, have vasoactive or procoagulant effects leading to thrombocytopenia, disseminated intravascular coagulation and vasculitis, which may result in stroke. It is challenging to treat stroke in patients with dengue because of the difficulty of administering thrombolytic agents to patients with a bleeding tendency. Knowing the incidence of and risk factors for stroke in patients with dengue would be helpful. However, only a few cases of dengue-related hemorrhagic or ischemic stroke have been reported. The risk of stroke in patients with dengue remains unclear.

In Taiwan, patients with dengue are under surveillance by the Centers for Disease Control, R.O.C. (Taiwan) (known as the Taiwan CDC), through a routine laboratory-based screening and diagnosis system. All hospital-diagnosed cases of dengue must be reported to the Taiwan CDC for confirmation and subsequent surveillance. We conducted a population-based retrospective cohort study using data from the Taiwan National Health Insurance Research Database (NHIRD), to investigate the risk of stroke in patients with dengue.

Methods

Data source

For this retrospective cohort study, we retrieved data concerning patients with dengue from the NHIRD, which enrolled about 26 million residents in Taiwan between 1996 and 2013, covering more than 99% of the population of Taiwan. The database contained detailed health care information for each enrollee, with encryption to protect personal privacy. Disease identification in the NHIRD follows the International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM). Previous studies have validated the accuracy of disease diagnosis in the NHIRD.
including diagnosis of ischemic stroke, showing high sensitivity (94.5%–97.3%) and high positive predictive value (88.4%–97.8%).11,12 The Bureau of National Health Insurance in Taiwan routinely reviews medical charts and claims to ensure the validity and accuracy of data coding in the NHIRD.

**Study population and outcome**

The study population comprised 2 cohorts: the dengue and control cohorts. The dengue cohort consisted of all cases of dengue newly diagnosed in hospital between 2000 and 2012, specifically dengue fever (ICD-9-CM code 061) and dengue hemorrhagic fever (ICD-9-CM code 065.4). To avoid surveillance bias related to hospital admission, the control cohort consisted of hospital inpatients without a diagnosis of dengue. For each patient, the index date was defined as the date of first diagnosis of dengue fever or dengue hemorrhagic fever (dengue cohort) or the admission date (control cohort). We defined patients with separate diagnosis dates during the follow-up period as having repeat dengue infections.

The main study outcome was stroke (ICD-9-CM codes 430–437), as documented in hospital records. We also assessed hemorrhagic stroke (ICD-9-CM codes 430–432) and ischemic stroke (ICD-9-CM codes 433–434) in our stratified analysis. We excluded patients with stroke or late effects of stroke (ICD-9-CM codes 437), as documented in hospital records. We also assessed with stroke, including atrial fibrillation or flutter, cancer, chronic obstructive pulmonary disease (COPD), chronic renal failure, diabetes mellitus, dyslipidemia, heart failure, hypertension and ischemic heart disease.15,16 As a measure of the severity of stroke and underlying diseases, we assessed the total admission days for each participant.17,18 Appendix 1 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.170994/-/DC1) lists the detailed ICD-9-CM codes for covariables in this study. We also used hospitalization records to identify comorbidities, using validated algorithms.19

**Statistical analysis**

We tested the differences in baseline characteristics between the 2 cohorts by \( \chi^2 \) and 2-sample Student t tests. We used a
multivariable Cox proportional hazard model, with adjustment for sex, age, covariables and the competing risk of death, to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for stroke. We performed stratified subgroup analyses with both single-variable and multivariable Cox proportional hazard models. We also conducted sensitivity analyses with alternative controls matched by propensity score. We used the Kaplan–Meier method to compare the cumulative incidences of stroke between the 2 cohorts with the log-rank test. We verified the assumption of proportional hazards with the graphical plotting method. We tested the seasonality of stroke in this study with the χ² goodness-of-fit test.

We performed all statistical analyses with SAS statistical software, version 9.4 (SAS Institute), with significance set at α = 0.05.

**Ethics approval**
The study was approved by the Institutional Review Board of the China Medical University Hospital (CMUH104-REC2–115-CR2), which waived the requirement for informed consent because data in the NHIRD are de-identified.

**Results**
After matching, 13 787 patients were included in each of the dengue and control cohorts (Figure 1). The 2 cohorts had nearly equal proportions of females and males (Table 1), although the slightly greater proportion of males in the control cohort was statistically significant. No other baseline characteristics were significantly different. Most patients were between 31 and 60 years of age. The mean follow-up period was 7.58 and 7.89 years in the dengue and control groups, respectively. The top 5 reasons for admission for the control group were digestive disorders (e.g., peptic ulcer, diarrhea, hemorrhoids), cardiopulmonary disorders (e.g., hypertension, arrhythmia, ischemic heart), metabolic disorders (e.g., diabetes, dyslipidemia), trauma and genitourinary disorders (e.g., urolithiasis, chronic renal failure).

The overall incidence rate of stroke was higher in the dengue cohort than in the control cohort (5.33 v. 3.72 per 1000 person-years), with adjusted HR of 1.16 (95% CI 1.01–1.32) (Table 2). Females in the dengue cohort and patients without comorbidity in the dengue cohort had higher risk ratios for stroke than those in the control cohort (for females, adjusted HR 1.32, 95% CI...
1.07–1.62; for those with no comorbidities, adjusted HR 1.31, 95% CI 1.10–1.56). The proportion of patients with stroke who were admitted to the intensive care unit did not differ significantly between the dengue and control cohorts (28/557 [5.0%] v. 24/405 [5.9%], p = 0.5).

**Time trends for risk of stroke**
The incidence rate of stroke in the dengue cohort showed a time-dependent trend during the follow-up period (Table 3). The risk of stroke in the dengue cohort, relative to the control cohort, was highest in the first 2 months (25.53 per 1000 person-years; adjusted HR 2.49, 95% CI 1.48–4.18) and then declined as the follow-up period increased. The risk of hemorrhagic and ischemic strokes showed a similar trend: highest in the first 2 months (for hemorrhagic stroke, adjusted HR 8.72, 95% CI 1.10–68.9; for ischemic stroke, adjusted HR 2.90, 95% CI 1.35–6.26). The difference in cumulative incidence of stroke between the 2 cohorts appeared early in the follow-up period (Appendix 2, Part 1, available at

### Table 2: Comparison of incidence and hazard ratio of stroke between dengue and control cohorts

| Variable | Control cohort | Dengue cohort | Crude HR (95% CI) | Adjusted HR† (95% CI) |
|----------|----------------|---------------|-------------------|----------------------|
|          | No. of events  | PY Rate*      | No. of events     | PY Rate*             |                      |
| Total stroke | 405 108 847 3.72 | 557 104 563 5.33 | 1.43 (1.26–1.63) | 1.16 (1.01–1.32) |
| Sex      |                |               |                   |                      |
| Female   | 145 53 320 2.72 | 251 53 298 4.71 | 1.72 (1.40–2.11) | 1.32 (1.07–1.62) |
| Male     | 260 55 527 4.68 | 306 51 265 5.97 | 1.28 (1.08–1.51) | 1.06 (0.89–1.25) |
| Stratified by age, yr | | | | |
| ≤30      | 7 19 885 0.35 | 9 28 177 0.32 | 0.87 (0.32–2.33) | 0.84 (0.31–2.27) |
| 31–60    | 183 76 709 2.39 | 193 54 186 3.56 | 1.51 (1.23–1.85) | 1.48 (1.21–1.82) |
| >60      | 215 12 252 17.55 | 355 22 200 15.99 | 0.90 (0.76–1.07) | 0.99 (0.83–1.17) |
| Comorbidity |            |               |                   |                      |
| No       | 215 98 654 2.18 | 360 93 640 3.84 | 1.79 (1.51–2.12) | 1.31 (1.10–1.56) |
| Yes      | 190 10 193 18.64 | 197 10 924 18.03 | 0.96 (0.78–1.17) | 0.91 (0.75–1.12) |

Note: CI = confidence interval, HR = hazard ratio, PY = person-years.
*Incidence rate, per 1000 person-years.
†Adjusted for sex, age, total days of admission and comorbidity in Cox proportional hazards regression.

### Table 3: Risk trends for stroke in each cohort, stratified by follow-up period and type of stroke

| Type of stroke and follow-up period, mo | Control cohort | Dengue cohort | Crude HR (95% CI) | Adjusted HR† (95% CI) |
|---------------------------------------|----------------|---------------|-------------------|----------------------|
|                                      | No. of events  | PY Rate*      | No. of events     | PY Rate*             |                      |
| Any stroke                            |                |               |                   |                      |
| ≤2                                    | 19 2292 8.29   | 58 2272 25.53 | 3.06 (1.82–5.13) | 2.49 (1.48–4.18)     |
| 3–12                                  | 42 11 351 3.7  | 57 11 250 5.07 | 1.37 (0.92–2.04) | 1.18 (0.79–1.75)     |
| >12                                   | 344 95 204 3.61 | 442 91 041 4.85 | 1.34 (1.17–1.55) | 1.13 (0.98–1.30)     |
| Hemorrhagic stroke                    |                |               |                   |                      |
| ≤2                                    | 1 2293 0.44    | 10 2279 4.39  | 10.01 (1.28–78.17) | 8.72 (1.10–68.9)     |
| 3–12                                  | 8 11 376 0.7   | 14 11 303 1.24 | 1.76 (0.74–4.20) | 1.57 (0.67–3.69)     |
| >12                                   | 58 96 593 0.6  | 74 92 931 0.80 | 1.31 (0.93–1.85) | 1.17 (0.83–1.65)     |
| Ischemic stroke                       |                |               |                   |                      |
| ≤2                                    | 8 2293 3.49    | 29 2276 12.74 | 3.63 (1.66–7.94) | 2.90 (1.35–6.26)     |
| 3–12                                  | 20 11 367 1.76 | 26 11 282 2.3  | 1.31 (0.73–2.34) | 1.09 (0.61–1.94)     |
| >12                                   | 180 96 011 1.87 | 258 91 954 2.81 | 1.51 (1.24–1.82) | 1.21 (1.00–1.47)     |

Note: CI = confidence interval, HR = hazard ratio, PY = person-years.
*Incidence rate, per 1000 person-years.
†Adjusted for sex, age, total admission days and comorbidity in Cox proportional hazards regression.
www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.170994/-/DC1) and was statistically significant ($p < 0.001$). The result of seasonality testing showed no significant seasonal effect ($p = 0.5$).

**Risk factors for stroke**

Appendix 2, Part 2 shows that patients with dengue hemorrhagic fever had the highest incidence rate of stroke (7.92 per 1000 person-years), with an adjusted HR of 1.40 (95% CI 1.10–1.77), followed by patients with repeat dengue infection (6.85 per 1000 person-years; adjusted HR 1.19, 95% CI 0.80–1.77) and patients with dengue fever (4.96 per 1000 person-years; adjusted HR 1.14, 95% CI 1.00–1.31).

In the multivariable analysis of risk factors for stroke (Appendix 2, Part 3), dengue was an independent risk factor for stroke (adjusted HR 1.18, 95% CI 1.03–1.34). Diabetes was the highest risk factor for stroke (adjusted HR 2.01, 95% CI 1.66–2.43), followed by dyslipidemia (adjusted HR 1.49, 95% CI 1.15–1.92), male sex (adjusted HR 1.46, 95% CI 1.29–1.67), hypertension (adjusted HR 1.45, 95% CI 1.20–1.76) and age (adjusted HR 1.07 per year, 95% CI 1.06–1.07). The sensitivity analyses with alternative controls matched by propensity score had results similar to those of the main analyses (Appendix 2, Parts 4 and 5).

**Interpretation**

This study showed that patients with dengue had an increased risk of stroke, and this risk was time-dependent, as high as 2.49 times relative to control patients in the first 2 months. Patients with dengue who were male, who were older than 60 years or who had comorbidities had a higher incidence of stroke. The increased risk ratio for stroke in patients with dengue was greater for females and for those without comorbidity. It may be that male sex and comorbidities (including diabetes, dyslipidemia and hypertension) are stronger risk factors for stroke than dengue, and thus may mask the effects of dengue.

We found that patients with dengue had a higher risk of both hemorrhagic and ischemic stroke. Compared with previous studies reporting more hemorrhagic strokes than ischemic strokes among patients with dengue, we observed more ischemic strokes. This difference may be related to universal screening for and surveillance of dengue, and to high medical accessibility in Taiwan, which could improve the early detection of ischemic stroke among patients with dengue. It is uncertain whether reported dengue-related hemorrhagic strokes were due to direct hemorrhage or to hemorrhagic conversion from ischemic stroke. Carod-Artal and associates also assumed that dengue-related ischemic strokes might be underestimated. In our study, patients with dengue hemorrhagic fever had a higher risk of stroke than patients with dengue fever, which indicates that the pathogenesis of dengue hemorrhagic fever may play a role in the occurrence of stroke.

The mechanisms of dengue-related stroke are under investigation. Multiple pathways have been proposed, with the major focus on endothelial dysfunction leading to plasma leakage. Dengue virus could infect immune cells, inducing complex cascades of inflammatory mediators, such as cytokines, chemokines and complement. The interaction of these mediators with endothelial cells increases endothelial permeability and reduces the integrity of the endothelial barrier. Moreover, cross-reaction of anti-NS1 antibodies and direct viral infection of endothelial cells and platelets contribute to hemorrhage, thrombocytopenia and plasma leakage. These immune-mediated mechanisms of dengue hemorrhagic fever in peripheral blood have also been found in the brain, where they cause breakdown of the blood-brain barrier, leukocyte infiltration and local inflammation, followed by vasodilation, thromboembolism, cerebral edema, ischemia and hemorrhage. A few case reports have shown atrial fibrillation as a complication of severe dengue, which may predispose these patients to stroke.

The time trends for dengue-related stroke in this study suggest that the effects of dengue on stroke may be acute rather than chronic. Previous studies found that the inflammatory mediators and antigen–antibody complex caused by dengue were transient. Furthermore, reported cases of dengue-related stroke have ranged from 2 to 22 days after onset of fever.

**Limitations**

This study had some limitations. In Taiwan, cases of dengue are clustered seasonally. However, we found no significant seasonality leading to bias for the stroke cases in our study. This finding corresponds to that of a prior study indicating that there is no seasonality to ischemic stroke in Taiwan. To ensure sufficient sample size and case ascertainment for patients with dengue, we used hospital records for the whole population of Taiwan; however, these records lack details about disease severity and medications. Therefore, we adjusted the data for total admission days, a measure that is highly correlated with disease severity. Total admission days and the proportion of patients admitted to the intensive care unit were comparable between the 2 study groups. To address potential confounding related to medications, we performed a subgroup analysis of patients without comorbidities, who would be less likely to receive medications such as anti-thrombotic or antihypertensive agents for stroke prevention; the results were consistent with the main analysis, with a stronger effect. Thus, disease severity and medications are unlikely to have biased our conclusions. Information about smoking, diet, body mass index, daily activity and ethnicity is not recorded in the NHIRD, so we could not adjust for these confounding variables. We used COPD as a surrogate in covariable adjustment. The NHIRD does not record laboratory data, so we were unable to perform further analysis on the effects of different dengue serotypes or the patients’ bleeding profiles or inflammatory markers. Given the inherent limitations of administrative data, systematic bias, such as coding errors, was inevitable.

**Conclusion**

In this population-based study, the presence of dengue was associated with an increased risk of stroke. The effect of dengue on stroke may be acute rather than chronic. Clinicians in dengue-endemic areas should be aware of this association, especially for patients with dengue who have neurologic deficits or for patients with stroke who have unexplained fever. Our findings may help with clinical risk evaluation and may serve as a basis for further investigation of the pathogenesis of dengue-related stroke.
References

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013;496:504-7.

2. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: World Health Organization; 1997.

3. Dengue: guidelines for diagnosis, treatment, prevention and control. Geneva: World Health Organization; 2009.

4. Carod-Artal FJ, Wichmann O, Farrar J, et al. Neurological complications of dengue virus infection. Lancet Neurol 2013;12:906-19.

5. Sam JE, Gee TS, Nasser AW. Deadly intracranial bleed in patients with dengue fever: a series of nine patients and review of literature. J Neurosci Rural Pract 2016;7:423-34.

6. Nanda SK, Jayalakshmi S, Mohandas S. Pediatric ischemic stroke due to dengue vasculitis. Pediatr Neurol 2014;51:570-2.

7. Mathew S, Pandian JD. Stroke in patients with dengue. J Stroke Cerebrovasc Dis 2010;19:253-6.

8. Kumar R, Prakash O, Sharma B. Intracranial hemorrhage in dengue fever: management and outcome: a series of 5 cases and review of literature. Surg Neurol 2009;72:429-33.

9. Liou LM, Lan SH, Lai CL. Dengue fever with ischemic stroke: a case report. Neurologist 2008;14:40-2.

10. Shu PY, Chang SF, Yueh YY, et al. Current status of dengue diagnosis at the center for disease control, Taiwan. Dengue Bull 2004;28:107-17.

11. Hsieh CY, Chen CH, Li CY, et al. Validating the diagnosis of acute ischemic stroke in a national health insurance claims database. J Formos Med Assoc 2015;114:254-9.

12. Cheng CL, Kao YHY, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011;20:236-42.

13. Elkind MS, Carty CL, O’Meara ES, et al. Hospitalization for infection and risk of acute ischemic stroke: the Cardiovascular Health Study. Stroke 2011;42:1851-6.

14. Fugate JE, Lyons JL, Thakur KT, et al. Infectious causes of stroke. Neurology 2013;71:1056-62.

15. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics — 2017 update: a report from the American Heart Association. Circulation 2017;135:e146-e603.

16. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010;65:956-62.

17. Appelros P. Prediction of length of stay for stroke patients. Acta Neurol Scand 2007;116:15-9.

18. Chang KC, Tseng MC, Weng HH, et al. Prediction of length of stay of first-ever ischemic stroke. Stroke 2002;33:2670-4.

19. Sung SF, Hsieh CY, Lin HJ, et al. Validation of algorithms to identify stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage in an administrative claims database. Int J Cardiol 2016;215:277-82.

20. Malavige GN, Ogg GS. Pathogenesis of vascular leak in dengue virus infection. Immunology 2017;151:261-9.

21. Basu A, Chaturvedi UC. Vascular endothelium: the battlefield of dengue viruses. FEMS Immunol Med Microbiol 2008;53:287-99.

22. Sun DS, Chang YC, Lien TS, et al. Endothelial cell sensitization by death receptor fractions of an anti-dengue nonstructural protein 1 antibody induced plasma leakage, coagulopathy, and mortality in mice. J Immunol 2015;195:2743-53.

23. Hottz E, Tolley ND, Zimmerman GA, et al. Platelets in dengue infection. Drug Discov Today Dis Mech 2011;8:e33-8.

24. Kim JY, Kawabori M, Yenari MA. Innate inflammatory responses in stroke: mechanisms and potential therapeutic targets. Curr Med Chem 2014;21:2076-97.

25. Pahadiya HR, Veeram Parmar HK, Sagar A. Atrial fibrillation due to acute myocarditis during dengue haemorrhagic fever. J Clin Diag Res 2015;9:0101-2.

26. Mahmood M, Darul NDM, Mokhtar I, et al. Atrial fibrillation as a complication of dengue hemorrhagic fever: non-self-limiting manifestation. Int J Infect Dis 2009;13:e316-8.

27. Nationwide weekly confirmed cases of indigenous dengue fever, year over year comparison [figure]. Taipei City (Republic of China): Centers for Disease Control; 2017.

28. Lee HC, Hu CJ, Chen CS, et al. Seasonal variation in ischemic stroke incidence and association with climate: a six-year-population-based study. Chronobiol Int 2008;25:938-49.

Competing interests: None declared.

This article has been peer reviewed.

Affiliations: Department of Radiology (Li), E-DA Hospital; Department of Radiology (Huang), Kaohsiung Municipal Min-Sheng Hospital, Kaohsiung, Taiwan; Management Office for Health Data (Su) and Department of Nuclear Medicine and PET Center (Kao), China Medical University Hospital; College of Medicine (Su) and Graduate Institute of Clinical Medical Science, School of Medicine, College of Medicine (Kao), China Medical University; Department of Bioinformatics and Medical Engineering (Kao), Asia University, Taichung, Taiwan

Contributors: Hao-Ming Li, Ying-Kai Huang and Chia-Hung Kao conceived and designed the study. All of the authors collected and organized the data. Hao-Ming Li and Ying-Kai Huang interpreted the data. Yuan-Chih Su performed the statistical analysis. All of the authors drafted and revised the manuscript for important intellectual content. Chia-Hung Kao supervised the study and provided administrative support. All of the authors gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

Funding: This study was supported in part by the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-212-123004); the China Medical University Hospital; Academia Sinica Stroke Biosignature Project (BM1070101002); the Taiwan Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005); the Tseng-Lien Lin Foundation, Taichung, Taiwan; the Taiwan Brain Disease Foundation, Taipei, Taiwan; and the Katsuzo and Kiyo Aoshima Memorial Funds of Japan. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. No additional external funding was received for this study.

Accepted: Nov. 16, 2017

Correspondence to: Chia-Hung Kao, d10040@mail.cmuh.org.tw